MEDB-65. Molecular subclassification of a national cohort of pediatric medulloblastoma based on methylation profile

Lide Alaña, Idoia Martin-Guerrero, Aurora Navajas, Laura Zaldumbide, Lorena Mosteiro, Edward C Schwalbe, Debbie Hicks, Steven C Clifford, Miguel García-Ariza

Research output: Contribution to journalMeeting Abstractpeer-review

24 Downloads (Pure)


INTRODUCTION: Pediatric Medulloblastoma (MB) accounts for approximately 20% of all childhood brain tumors. Molecular subgroups namely WNT, SHH, Group 3 and Group 4, exhibit divergent biology, and clinical outcomes. DNA methylation analysis is a robust option to classify pediatric MB into molecular subgroups, which allows the optimization of diagnosis and stratification of the treatment. We review the first experience of molecular subclassification carried out at the national level in our country.
METHODS: Multi-center centralized prospective and retrospective study of frozen tumor samples at diagnosis from pediatric MB patients diagnosed in Spanish hospitals, from April 2021 to December 2021. A registry was created with histology review, immunohistochemical (IHC) subgrouping, and a molecular subgrouping based on the Minimal Methylation Classifier (MIMIC) from Schwalbe et al., 2017. The time from the sample centralized reception to the study result was also collected. RESULTS: 25 frozen MB tumor samples from patients at diagnosis were included. 6 were retrospective and 19 prospective. IHC classified 19 cases (76%) as non-WNT/non-SHH MBs, 3 (12%) as WNT-activated and 3 (12%) as SHH-activated. MIMIC classified, in the non-WNT/non-SHH, 6 tumors (24%) as Group 3 and 13 (52%) as Group 4. 2 cases (8%) were WNT-activated MBs and 3 (12%) were SHH-activated MBs. Only 1 case (4%) was unclassified by MIMIC (WNT using IHC). Comparing both methods (IHC and MIMIC), diagnosis agreed in 96% of cases. The response time ranged from 5 to 10 days.
CONCLUSIONS: DNA methylation profiling has proven to be a robust and quick option to classify MB into subgroups and it correlates with the IHC diagnosis. This tool was successfully implemented in our national routine diagnosis, enabling a reliable and rapid molecular subgrouping classification.
Original languageEnglish
Pages (from-to)i121-i121
Number of pages1
Issue numberSupplement_1
Early online date3 Jun 2022
Publication statusPublished - 3 Jun 2022
Event20th International Symposium on Pediatric Neuro-Oncology - Congress Center, Hamburg, Germany
Duration: 12 Jun 202215 Jun 2022


Dive into the research topics of 'MEDB-65. Molecular subclassification of a national cohort of pediatric medulloblastoma based on methylation profile'. Together they form a unique fingerprint.

Cite this